Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles

Long-acting parenteral (LAP) antiretroviral drugs have generated considerable interest for treatment and prevention of HIV-1 infection. One new LAP is cabotegravir (CAB), a highly potent integrase inhibitor, with a half-life of up to 54 days, allowing for every other month parenteral administrations...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Biomaterials
Autores principales: Zhou, Tian, Su, Hang, Dash, Prasanta, Lin, Zhiyi, Shetty, Bhagya Laxmi Dyavar, Kocher, Ted, Szlachetka, Adam, Lamberty, Benjamin, Fox, Howard S., Poluektova, Larisa, Gorantla, Santhi, McMillan, JoEllyn, Gautam, Nagsen, Mosley, R. Lee, Alnouti, Yazen, Edagwa, Benson, Gendelman, Howard E.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5926202/
https://ncbi.nlm.nih.gov/pubmed/29059541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.biomaterials.2017.10.023
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares